However, there is some promise in utilizing the lipid-lowering medication gemfibrozil which activates PPAR-α and was shown to both inhibit the production of Aβ via upregulation of ADAM10 and stimulate cellular clearance by inducing lysosomal biogenesis in the 5XFAD transgenic model of AD [33,34,35,36,37]. The gene discussed is ADAM10; the disease is Alzheimer disease.